Advanced

Tumor-specific expression of HMG-CoA reductase in a population-based cohort of breast cancer patients.

Gustbée, Emma; Tryggvadottir, Helga LU ; Markkula, Andrea LU ; Simonsson, Maria LU ; Nodin, Björn LU ; Jirström, Karin LU ; Rose, Carsten LU ; Ingvar, Christian LU ; Borgquist, Signe LU and Jernström, Helena LU (2015) In BMC Clinical Pathology 15.
Abstract
The mevalonate pathway synthetizes cholesterol, steroid hormones, and non-steriod isoprenoids necessary for cell survival. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) is the rate-limiting enzyme of the mevalonate pathway and the target for statin treatment. HMGCR expression in breast tumors has recently been proposed to hold prognostic and treatment-predictive information. This study aimed to investigate whether HMGCR expression in breast cancer patients was associated with patient and tumor characteristics and disease-free survival (DFS).
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
BMC Clinical Pathology
volume
15
publisher
BioMed Central
external identifiers
  • pmid:26109908
  • scopus:84929991987
ISSN
1472-6890
DOI
10.1186/s12907-015-0008-2
project
CREATE Health
language
English
LU publication?
yes
id
6fa86209-d806-44ce-bce0-6277f43f3b19 (old id 7477960)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/26109908?dopt=Abstract
date added to LUP
2015-07-10 22:21:29
date last changed
2017-11-12 03:34:05
@article{6fa86209-d806-44ce-bce0-6277f43f3b19,
  abstract     = {The mevalonate pathway synthetizes cholesterol, steroid hormones, and non-steriod isoprenoids necessary for cell survival. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) is the rate-limiting enzyme of the mevalonate pathway and the target for statin treatment. HMGCR expression in breast tumors has recently been proposed to hold prognostic and treatment-predictive information. This study aimed to investigate whether HMGCR expression in breast cancer patients was associated with patient and tumor characteristics and disease-free survival (DFS).},
  articleno    = {8},
  author       = {Gustbée, Emma and Tryggvadottir, Helga and Markkula, Andrea and Simonsson, Maria and Nodin, Björn and Jirström, Karin and Rose, Carsten and Ingvar, Christian and Borgquist, Signe and Jernström, Helena},
  issn         = {1472-6890},
  language     = {eng},
  publisher    = {BioMed Central},
  series       = {BMC Clinical Pathology},
  title        = {Tumor-specific expression of HMG-CoA reductase in a population-based cohort of breast cancer patients.},
  url          = {http://dx.doi.org/10.1186/s12907-015-0008-2},
  volume       = {15},
  year         = {2015},
}